Thu, Mar 5, 2015, 4:20 AM EST - U.S. Markets open in 5 hrs 10 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

plagioclase2002 3 posts  |  Last Activity: Feb 5, 2015 2:07 PM Member since: May 13, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    nobdy believes in this technology anymore

    by aawilliam2003 Feb 4, 2015 9:46 PM
    plagioclase2002 plagioclase2002 Feb 5, 2015 2:07 PM Flag

    I wish all those fighting cancer success. Nothing is proved [immunotherapy] on solid tumors. I do know that custom treatments like this are fantasticality expensive. Perhaps the first csc drug to market will attract attention.

  • plagioclase2002 by plagioclase2002 Jan 27, 2015 7:08 AM Flag

    The price was certainly lower than expected. Many biotechs have been raising $ since the first of the year. No pre offering stockholder has a profit. The ones in shock are those who participated in the original offerings [$10 & $15] & saw 3 years of progress. However, this is part of the risk investing in any venture capital [no product, no cash flow] firm. The stock looks attractive here on a risk-reward & timing [operational] basis. Looking for positives: money in hand early, $ until 2017, insiders participated, company retained 100% of benefits.

  • plagioclase2002 by plagioclase2002 Jan 11, 2015 2:50 PM Flag

    The thing that received my attention was the number of leads,teasers, that have resulted from their ongoing work. The company went public exactly 3 years ago @ $10. I wonder what it would sell for if going public for the first time now. Certainly more than the present price. I do recall that the base for Genzyme was also an orphan drug.

SNTA
2.43+0.05(+2.10%)Mar 4 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.